MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
Nyenta.com/10191366

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MEI Pharma, Inc. ("MEI" or the "Company") (NASDAQ: MEIP) on behalf of MEI stockholders. Our investigation concerns whether MEI has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On May 13, 2022, after market hours, MEI Pharma announced restatements of its financial statements for certain quarters for 2020 and 2021. In part, MEI Pharma stated, "[R]evenue was overstated in some quarters and understated in other quarters in the Company's financial statements during 2020 and 2021. The Company will therefore reinstate its previously filed annual and quarterly financial statements for periods from June 30, 2020 forward."

More on Nyenta.com

• Global X ETFs Expands its Lineup of Options-Based Strategies with Two Innovative Actively Managed Funds
• The LankyBox Toy Line By Bonkers Toys Will Have Fans Unboxing The Fun For The Very First Time
• RFP Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Resolute Forest Products Inc. Is Fair to Shareholders
• Evolve IP & Anywhere365 Group Create an Enterprise-Grade Receptionist Solution
• Arsenal Capital Partners Adds Marc Tremblay as an Operating Partner Focused on Industrial Technologies

On this news, MEI Pharma share prices fell to $0.0242, or 4.6%, to open at $0.4958 per share on May 16, 2022.

If you purchased or otherwise acquired MEI shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

More on Nyenta.com

• Riskified and Axerve Help KIKO Milano Boost Cart Conversions Under PSD2 by Maximizing TRA (Transaction Risk Analysis)
• ING Ventures Invests in OpenFin
• A New York Dental Anesthesiologist launches top care that travels to you
• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Target Corporation - TGT
• Shareholder Alert - The M&A Class Action Firm is Investigating the Merger - MANT, TPTX, BHVN, MN, HMTV, CVET

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

---

Show All News | Report Violation